請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19369完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王錦堂(Jin-Town Wang) | |
| dc.contributor.author | I-Cheng Hung | en |
| dc.contributor.author | 洪一琤 | zh_TW |
| dc.date.accessioned | 2021-06-08T01:55:46Z | - |
| dc.date.copyright | 2016-08-26 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-07-07 | |
| dc.identifier.citation | 1. Murray, P., et al., Medical Microbiology. 7 ed. 2012.
2. Sikarwar, A.S. and H.V. Batra, Identification of Klebsiella Pneumoniae by CapsularPolysaccharide Polyclonal Antibodies International Journal of Chemical Engineering and Applications, 2011. 2(2): p. 130-134. 3. Mizuta, K., et al., Virulence for mice of Klebsiella strains belonging to the O1 group: relationship to their capsular (K) types. Infect Immun, 1983. 40(1): p.56-61. 4. Hsu, C.R., et al., Isolation of a bacteriophage specific for a new capsular type of Klebsiella pneumoniae and characterization of its polysaccharide depolymerase. PLoS One, 2013. 8(8): p. e70092. 5. Pan, Y.J., et al., Capsular polysaccharide synthesis regions in Klebsiella pneumoniae serotype K57 and a new capsular serotype. J Clin Microbiol,2008. 46(7): p. 2231-40. 6. Siu, L.K., et al., Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet Infect Dis, 2012. 12(11): p. 881-7. 7. Wang, J.H., et al., Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis, 1998. 26(6): p. 1434-8. 8. Ko, W.C., et al., Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis, 2002. 8(2): p. 160-6. 9. Blair, J.M., et al., Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol, 2015. 13(1): p. 42-51. 10. Cook, M., E. Molto, and A. C., Fluorochrome labeling in Roman period skeletons from Dakhleh Oasis. Egypt. Am. J. Phys. Anthropol, 1989. 80: p. 137-143. 11. Antimicrobial Resistance: Global Report on Surveillance 2014, in World Health Organization. 2014. 12. Global Risks 2014 Report, in World Economic Forum. 2014. 13. Pitout, J.D. and K.B. Laupland, Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis, 2008. 8(3): p. 159-66. 14. Lombardi, F., et al., Emergence of Carbapenem-Resistant Klebsiella pneumoniae: Progressive Spread and Four-Year Period of Observation in a Cardiac Surgery Division. Biomed Res Int, 2015. 2015: p. 871947. 15. Srinivasan, A. and J.B. Patel, Klebsiella pneumoniae carbapenemaseproducing organisms: an ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol, 2008. 29(12): p. 1107-9. 16. Sisto, A., et al., Carbapenem non-susceptible Klebsiella pneumoniae from Micronet network hospitals, Italy, 2009 to 2012. Euro Surveill, 2012. 17(33). 17. Annual report of Taiwan Nosocomial Infection Surveillance Systems. 2011, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 18. Papp-Wallace, K.M., et al., Carbapenems: past, present, and future. Antimicrob Agents Chemother, 2011. 55(11): p. 4943-60. 19. Doumith, M., et al., Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother, 2009. 63(4): p. 659-67. 20. Queenan, A.M. and K. Bush, Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev, 2007. 20(3): p. 440-58, table of contents. 21. Tipper, D.J. and J.L. Strominger, Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci U S A, 1965. 54(4): p. 1133-41. 22. Bush, K., G.A. Jacoby, and A.A. Medeiros, A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother, 1995. 39(6): p. 1211-33. 23. Gupta, N., et al., Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis, 2011. 53(1): p. 60-7. 24. Lartigue, M.F., et al., Ertapenem resistance of Escherichia coli. Emerg Infect Dis, 2007. 13(2): p. 315-7. 25. Lee, K., et al., Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases comediated by porin loss. Int J Antimicrob Agents, 2007. 29(2): p. 201-6. 26. Martinez-Martinez, L., Extended-spectrum beta-lactamases and the permeability barrier. Clin Microbiol Infect, 2008. 14 Suppl 1: p. 82-9. 27. Bradford, P.A., et al., Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC betalactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother, 1997. 41(3): p. 563-9. 28. Skurnik, D., et al., Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extendedspectrum beta-lactamase. J Med Microbiol, 2010. 59(Pt 1): p. 115-9. 29. Chiu, S.K., et al., National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS One, 2013. 8(7): p. e69428. 30. Jones, R.N., M.A. Pfaller, and M.S. Group, Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect, 2003. 9(7): p. 708-12. 31. Neuner, E.A., et al., Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis, 2011. 69(4): p. 357-62. 32. Bialvaei, A.Z. and H. Samadi Kafil, Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin, 2015. 31(4): p. 707-21. 33. Marquardt, J.L., et al., Cloning and sequencing of Escherichia coli murZ and purification of its product, a UDP-N-acetylglucosamine enolpyruvyl transferase. J Bacteriol, 1992. 174(17): p. 5748-52. 34. Qureshi, Z.A., et al., Treatment outcome of acteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother, 2012. 56(4): p. 2108-13. 35. Tommasi, R., et al., ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov, 2015. 36. Hendlin, D., et al., Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science, 1969. 166(3901): p. 122-3. 37. Brown, E.D., et al., MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli. J Bacteriol, 1995. 177(14): p. 4194-7. 38. Marquardt, J.L., et al., Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin. Biochemistry, 1994. 33(35): p. 10646-51. 39. Skarzynski, T., et al., Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure, 1996. 4(12): p. 1465-74. 40. Kahan, F.M., et al., The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci, 1974. 235(0): p. 364-86. 41. Joukhadar, C., et al., Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother, 2003. 51(5): p. 1247-52. 42. Legat, F.J., et al., Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother, 2003. 47(1): p. 371-4. 43. Zeitlinger, M.A., et al., Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother, 2003. 47(11): p. 3548-53. 44. Schintler, M.V., et al., High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother, 2009. 64(3): p. 574-8. 45. Matzi, V., et al., Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother, 2010. 65(5): p. 995-8. 46. Falagas, M.E., et al., Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis, 2008. 46(7): p. 1069-77. 47. Lu, C.L., et al., Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother, 2011. 55(9): p. 4295-301. 48. Falagas, M.E., et al., Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis, 2010. 10(1): p. 43-50. 49. Endimiani, A., et al., In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother, 2010. 54(1): p. 526-9. 50. Jiang, Y., et al., Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents, 2015. 45(1): p. 66-70. 51. Etienne, J., et al., Plasmid-mediated resistance to fosfomycin in Staphylococcus epidermidis. FEMS Microbiol Lett, 1989. 52(1-2): p. 133-7. 52. Kadner, R.J. and D.M. Shattuck-Eidens, Genetic control of the hexose phosphate transport system of Escherichia coli: mapping of deletion and insertion mutations in the uhp region. J Bacteriol, 1983. 155(3): p. 1052-61. 53. Island, M.D. and R.J. Kadner, Interplay between the membrane-associated UhpB and UhpC regulatory proteins. J Bacteriol, 1993. 175(16): p. 5028-34. 54. Elvin, C.M., C.M. Hardy, and H. Rosenberg, Pi exchange mediated by the GlpTdependent sn-glycerol-3-phosphate transport system in Escherichia coli. J Bacteriol, 1985. 161(3): p. 1054-8. 55. Dahl, J.L., B.Y. Wei, and R.J. Kadner, Protein phosphorylation affects binding of the Escherichia coli transcription activator UhpA to the uhpT promoter. J Biol Chem, 1997. 272(3): p. 1910-9. 56. Ambudkar, S.V., V. Anantharam, and P.C. Maloney, UhpT, the sugar phosphate antiporter of Escherichia coli, functions as a monomer. J Biol Chem, 1990. 265(21): p. 12287-92. 57. Cordaro, J.C., et al., Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J Bacteriol, 1976. 128(3): p.785-93. 58. Alper, M.D. and B.N. Ames, Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: positive selection of Salmonella typhimurium cya and crp mutants. J Bacteriol, 1978. 133(1): p. 149-57. 59. Sakamoto, Y., et al., Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci Biotechnol Biochem, 2003. 67(9): p. 2030-3. 60. Ramilo, C., et al., Detection of the covalent intermediate of UDP-Nacetylglucosamine enolpyruvyl transferase by solution-state and timeresolved solid-state NMR spectroscopy. Biochemistry, 1994. 33(50): p. 15071-9. 61. De Smet, K.A., et al., Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from Mycobacterium tuberculosis. Microbiology, 1999. 145 ( Pt 11): p. 3177-84. 62. McCoy, A.J., R.C. Sandlin, and A.T. Maurelli, In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance. J Bacteriol, 2003. 185(4): p. 1218-28. 63. Jiang, S., et al., Lyme disease enolpyruvyl-UDP-GlcNAc synthase: fosfomycinresistant MurA from Borrelia burgdorferi, a fosfomycin-sensitive mutant, and the catalytic role of the active site Asp. Biochemistry, 2011. 50(12): p. 2205- 12. 64. Wachino, J., et al., Prevalence of fosfomycin resistance among CTX-Mproducing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother, 2010. 54(7): p. 3061-4. 65. Ho, P.L., et al., Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. J Med Microbiol, 2013. 62(Pt 11): p. 1707-13. 66. Ho, P.L., et al., Plasmid-mediated fosfomycin resistance in Escherichia coli isolated from pig. Vet Microbiol, 2013. 162(2-4): p. 964-7. 67. Ho, P.L., et al., Dissemination of plasmid-mediated fosfomycin resistance fosA3 among multidrug-resistant Escherichia coli from livestock and other animals. J Appl Microbiol, 2013. 114(3): p. 695-702. 68. Arca, P., G. Reguera, and C. Hardisson, Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother, 1997. 40(3): p. 393-9. 69. Miller, V.L. and J.J. Mekalanos, A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol, 1988. 170(6): p. 2575-83. 70. Herrero, M., V. de Lorenzo, and K.N. Timmis, Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram-negative bacteria. J Bacteriol, 1990. 172(11): p. 6557-67. 71. Hsieh, P.F., et al., Serum-induced iron-acquisition systems and TonB contribute to virulence in Klebsiella pneumoniae causing primary pyogenic liver abscess. J Infect Dis, 2008. 197(12): p. 1717-27. 72. Green, M.R., J. Sambrook, and J. Sambrook, Molecular cloning : a laboratory manual. Cold Spring Harbor Press, 2012. 4th 73. Shen, P., et al., Complete nucleotide sequence of pKP96, a 67 850 bp multiresistance plasmid encoding qnrA1, aac(6')-Ib-cr and blaCTX-M-24 from Klebsiella pneumoniae. J Antimicrob Chemother, 2008. 62(6): p. 1252-6. 74. Lee, S.Y., et al., Prevalence of acquired fosfomycin resistance among extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother, 2012. 67(12): p. 2843-7. 75. Ma, Y., et al., Characterization of fosA5, a new plasmid-mediated fosfomycin resistance gene in Escherichia coli. Lett Appl Microbiol, 2015. 60(3): p. 259-64. 76. Huang, Y., et al., Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science, 2003. 301(5633): p. 616-20. 77. Law, C.J., P.C. Maloney, and D.N. Wang, Ins and outs of major facilitator superfamily antiporters. Annu Rev Microbiol, 2008. 62: p. 289-305. 78. Kim, D.H., et al., Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry, 1996. 35(15): p. 4923-8. 79. Takahata, S., et al., Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents, 2010. 35(4): p. 333-7. 80. Yoon, H.J., et al., Crystal structure of UDP-N-acetylglucosamine enolpyruvyl transferase from Haemophilus influenzae in complex with UDP-N-acetylglucosamine and fosfomycin. Proteins, 2008. 71(2): p. 1032-7. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19369 | - |
| dc.description.abstract | 細菌抗藥性在全世界日趨嚴重，早期開發的磷黴素(fosfomycin)也重新被檢視。磷黴素毒性低、殺菌力強，對產生廣效性乙內醯胺酶(extended spectrum beta-lactamase, ESBL)分解酶的腸內菌具有高度感受性。我們測試50株由社區型原發性肝膿瘍(community-acquired pyogenic liver abscess)分離出的克雷伯氏肺炎桿菌以及52株carbapenem-resistant Klebsiella pneumoniae (CRKP)，發現共72株(70.6%)對磷黴素具感受性(MIC≦64μg/ml)，其中社區型肝膿瘍菌株100%(50/50)為感受型，而CRKP僅42.3%(22/52)為感受型。檢查18株抗磷黴素的CRKP帶有何種已知的抗藥機制，以功能分析證實4株帶有缺失的磷黴素運輸蛋白GlpT，藉由比對分析序列，發現此4株抗藥菌株的glpT確實有序列上的變異，並證實GlpT點突變(Glu299Asp)與磷黴素的抗藥性及sn-glycerol 3-phosphate (G3P)的運輸相關。挑選一株對磷黴素有高度抗藥性(MIC ≥2048 μg/ml)的菌株9921，建構突變株庫(transposon mutant library) 和基因表現庫(expression library)以尋找可能的未知抗藥機制。利用磷黴素篩選9921突變株庫後，得到一個突變株對磷黴素的最小抑菌濃度有下降，定序分析後得到跳躍子破壞的基因為pstA。篩選9921基因表現庫後，定序分析得到四段基因片段可能與磷黴素的抗藥性相關，並在大腸桿菌DH10B表現篩選到的基因片段和在磷黴素感受型臨床菌株NTUH-K2044中置換抗藥性候選基因，發現過量表現穀胱甘肽轉移酶(glutathione transferase)會造成磷黴素最小抑菌濃度上升。 | zh_TW |
| dc.description.abstract | Bacterial infections caused by antibiotic-resistant isolates have become a major health problem in recent years. Retrieval of old antibiotics, like fosfomycin, may be a short-term solution to the difficulties. Fosfomycin was recently revived as an antibiotic that could be effective against extended-spectrum-β-lactamase (ESBL) producers. We examined 50 Klebsiella pneumonia isolates causing community-acquired pyogenic liver abscess and 52 carbapenem-resistant K. pneumoniae (CRKP) isolates. There are 72 isolates(72/102, 70.6%) susceptible to fosfomycin (MIC≦64μg/ml) including 50 isolates causing community-acquired pyogenic liver abscess (100%) and 22 CRKP isolates (22/52, 42.3%). Among 18 fosfomycin-resistant strains, 4 strains are found to have defective sn-glycerol 3-phosphate transporter (GlpT) and harbor mutations in glpT gene. A single amino acid substitution (Glu299Asp) was demonstrated to contribute to fosfomycin resistance. In order to find novel fosfomycin-resistant mechanism(s), a transposon mutant library and expression library of a highly fosfomycin-resistant strain 9921 were constructed. Screening by fosfomycin revealed 1 mutant with decreased MIC and 5 expression clones which may contain fosfomycin-resistant genes. The gene pstA encoding phosphate transporter subunit was identified to be disrupted by transposon, and its functions in fosfomycin resistance need further studies. Overexpression of fosfomycin-resistant gene candidates in E. coli DH10B and replacement of fosfomycin-resistant gene candidates in NTUH-K2044, we found that overexpression of glutathione transferase causes the increase of fosfomycin MIC. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T01:55:46Z (GMT). No. of bitstreams: 1 ntu-105-R03445102-1.pdf: 2067106 bytes, checksum: b80055a49d1f55f47b9ca3e955769069 (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 口試委員會審定書 I
誌謝 II 中文摘要 III Abstract IV 目錄 V 表目錄 VII 圖目錄 VIII 第一章、緒論 1 1.1 克雷伯氏肺炎桿菌 (Klebsiella pneumoniae) 1 1.2 多重抗藥性細菌(multidrug-resistant bacteria)：全球醫療衛生的危機 1 1.3 抗碳青黴烯系列抗生素的克雷伯氏肺炎桿菌(carbapenem-resistant Klebsiella pneumoniae; CRKP) 2 1.4 臨床上對於多重抗藥性克雷伯氏肺炎桿菌的治療 4 1.5 老藥新用：磷黴素 (Fosfomycin) 5 1.6 磷黴素的抗藥機制 6 1.7 研究動機 8 第二章、材料與方法 9 2.1材料 9 2.1.1. 菌株(strains) 9 2.1.2. 質體(plasmids) 9 2.1.3. 培養基(media) 10 2.1.4. 抗生素(antibiotics) 10 2.1.5. 引子(primers) 10 2.2實驗方法 11 2.2.1. 抗生素感受性試驗(antimicrobial susceptibility test) 11 2.2.2. 運輸蛋白功能試驗(transporter functional test) 12 2.2.3. 胺基酸置換(amino acid substitution) 13 2.2.4. 基因表現庫(expression library) 13 2.2.5. 突變株庫(transposon mutant library) 19 2.2.6. 半隨機聚合酶連鎖反應(semi-random polymerase chain reaction) 20 2.2.7. 篩選突變株庫(screening) 21 第三章、實驗結果 22 3.1.1 磷黴素感受性試驗 22 3.1.2 定序分析抗磷黴素之多重抗藥性臨床菌株 22 3.1.3 內膜運輸蛋白GlpT與UhpT 功能分析 22 3.1.4 內膜運輸蛋白GlpT胺基酸置換 23 3.1.5 過量表現細胞壁合成蛋白MurA 23 3.1.6 改變磷黴素酵素基因之偵測 23 3.2.1 . 建構克雷伯氏肺炎桿菌突變株庫(transposon mutant library) 24 3.2.2 突變株多樣性測試 25 3.2.3 篩選突變庫之抗藥性候選基因(resistant gene candidate) 25 3.3.1 建構克雷伯氏肺炎桿菌基因表現庫(expression library) 26 3.3.2 篩選基因表現庫 26 3.3.3 再次轉型作用(retransformation)與DNA序列分析 26 3.3.4 在感受性菌株中表現抗藥性候選基因(candidate gene) 27 3.4 總結Summary 28 第四章、討論 29 第五章、參考文獻 33 附錄 54 | |
| dc.language.iso | zh-TW | |
| dc.title | 克雷伯氏肺炎桿菌對於磷黴素抗藥性之研究 | zh_TW |
| dc.title | Fosfomycin Resistance Mechanism(s)
in Klebsiella pneumoniae | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳世雄(Shih-Hsiung wu),董馨蓮(Shin-Lian Doong),蔡丰喬(Tsai Feng Chiao) | |
| dc.subject.keyword | 克雷伯氏肺炎桿菌,磷黴素,GlpT,UhpT,FosA,MurA,GST, | zh_TW |
| dc.subject.keyword | Klebsiella pneumoniae,fosfomycin,GlpT,UhpT,MurA,FosA,GST, | en |
| dc.relation.page | 55 | |
| dc.identifier.doi | 10.6342/NTU201600750 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2016-07-07 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 未授權公開取用 | 2.02 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。